The Centre François Baclesse is a regional cancer center (RCC). It is an institution that is a private organisation that participates in the public hospital service.
It is a member of the UNICANCER group, which unites 18 RCCs. UNICANCER is a hospital group dedicated exclusively to the fight against cancer. The Centre François Baclesse treats more than 6500 new patients annually, at all stages of disease. This activity is strongly rooted in the network of cancer care. Depending on the tumour location, this treatement involves 30M to 80% of all adult malignancies detected in the region.
Like all the RCCs, the Centre François Baclesse has a threefold mission in oncology :
Founded in 1923, the Cente has been located in the hospital area north of the city of Caen since 1973, close to its principal local partners : the Centre Hospitalier Universitaire (CHU), the Faculties of Medicine and Pharmacy, the School of Paramadicine, the National Large Heavy Ion (GANIL), the medical cyclotron (CYCERON), and the University.
The Centre François Baclesse has 875 employees, including 98 physicians and scientific personnel. Its annual operating budget is €83 million, and its investment capacity is €2.8 million. The Centre's revenue is derived mainly from its hospital billing services. Because to its status, it is also entitled to receive donations and bequets (art. L6162-2 of the Public Health Code). The Centre offers alternatives to full hospitalisation, such as day care and outpatient surgery. Il also offers rapid treatment regimes for breast and thyroid disease.
With over 56,000 visits per year and almost 25,500 hospitalisations, the Centre François Baclesse is the principal cancer focused location in the Normandy region. Each year, approximately 3350 patients undergo surgery, 2600 patients are treated with radiotherapy (approximately 48,450 radiotherapy sessions) and 13,800 chemotherapy sessions are delivred.
The external activity is very significant, particulary for breast care (nearly 6700 consultations), and imaging activites (19,100 computed tomography (CT) scans for 7300 passages, 4500 magnetic resonance imaging (MRI) scans and 6200 nuclear medicine examinations).
This oncology activity involves the totality of cancer disease in adults, with particular emphases on diagnostic breast examinations and breast cancer (about 1000 new breast cancer per year), bronchopulmonary and prostate cancer (more than 300 patients each year).
The radiotherapeutic technical capability of the RCC is in a position almost unique in France for conducting comparative evaluations of the CyberKnife(R) and TomoTherapy(R) systems, depending on the type of pathology.
The radiotherapy service of the RCC is the clinical and medical physics referent for the ARCHADE project, aimed at creating a European centre ofr research and development in cancer and Hadrontherapy, a promising innovation in radiotherapy, in Caen in 2016.